肥胖症与GLP-1药物：一项基于理赔数据的分析

aprilphotoⒸ123RF.com

PAPER

WHITE

and

Obesity

GLP-1Drugs

AClaims-BasedAnalysis

AFAIRHealthWhitePaper,May27,2025

Copyright2025,FAIRHealth,Inc.Allrightsreserved.

ObesityandGLP-1Drugs2

Summary

Obesityisacommonandseriousdisease.Inrecentyears,anewclassofmedicationsforobesityhasbecomeavailable:glucagon-likepeptide-1(GLP-1)receptoragonists.Inthisreport,FAIRHealthdelvesintoitsrepositoryofover51billioncommercialhealthcareclaimrecords,thenation’slargestsuch

database,toexaminetrendsinobesityandGLP-1drugprescriptionsamongadultpatientsduringthe

period2019-2024.Thisstudyfocusesontrendsindiagnosisofoverweight,obesityandtype2diabetes,aswellasGLP-1drugsandotherobesitytreatmentoptions(includingbariatricsurgeryandbehavioralhealthservices).Thekeyfindingsincludethefollowing:

•From2019to2024,thepercentageofadultpatientswithadiagnosisofoverweightorobesity

increasedfrom10.4percentin2019to15.7percentin2024,arelativeincreaseof50.7percent.AsdiscussedbelowintheResultssection,manyadultpatientswhoareoverweightorobesemaynotreceiveamedicaldiagnosisofoverweightorobesity.

1

•ThepercentageofadultpatientsprescribedanytypeofGLP-1drugincreasedfrom0.9percentofpatientsin2019to4.0percentofpatientsin2024,arelativeincreaseof363.7percent.

•AmongalladultpatientsprescribedaGLP-1drug,thepercentagewhohadanoverweightorobesitydiagnosisandnotype2diabetesdiagnosisincreasedfrom3.7percentin2019to16.5percentin2024,arelativeincreaseof344.4percent.

•OvertwopercentofadultpatientsnowtakeaGLP-1drugtotreatoverweightorobesity.Amongalladultpatients,thepercentagewhohadanoverweightorobesitydiagnosisandwere

prescribedaGLP-1drugincreasedfrom0.30percentin2019to2.05percentin2024,arelativeincreaseof586.7percent.Thepercentagewhoreceivedanoverweightorobesitydiagnosisbutnotype2diabetesdiagnosisincreased1,960.9percent,from0.03percentto0.67percent.

•Thepercentageofyoungeradults(aged18-39)prescribedaGLP-1drugincreasedfrom0.19percentin2019to1.33percentin2024,arelativeincreaseof587.8percent.

•Diagnosesofpancreatitisincreasedfrom0.17percentintheyearbeforethefirstGLP-1drugprescriptionto0.31percentintheyearafterforpatientswhodidnothaveatype2diabetes

diagnosis.Thiswasanincreaseofover80percent,thelargestpercentincreaseamongtheco-occurringdiagnosesexamined.

•From2019to2024,thepercentageofadultpatientswhohadbariatricsurgerydecreasedfrom

0.12percentin2019to0.07percentin2024,arelativedecreaseof41.8percent.

•From2019to2024,amongalladultpatientswithanoverweightorobesitydiagnosis,the

percentagewhowereprescribedaGLP-1drugbutdidnothavebariatricsurgeryincreasedfrom

2.5percentin2019to11.2percentin2024,arelativeincreaseof339.5percent.

•In2024,over80percentofpatientswithanoverweightorobesitydiagnosisdidnotreceivea

GLP-1prescription,bariatricsurgeryorbehavioralhealthservice.Only11.2percentofsuch

patientsreceivedaGLP-1prescription,6.3percentreceivedbehavioralhealthservicesand0.28percenthadbariatricsurgery.

•TheuseofbehavioralhealthservicesdecreaseddramaticallyforpatientsprescribedGLP-1

drugsduringthestudyperiod.Outofallpatientswithanoverweightorobesitydiagnosiswho

wereprescribedaGLP-1drug,thepercentageofpatientswhohadbehavioralhealthservicesrelatedtotheirconditiondeclinedfrom2019to2024.In2019,47.2percentofsuchpatientshad

1SaraN.Bleich,OctaviaPicket-BlakelyandLisaA.Cooper,“PhysicianPracticePatternsofObesityDiagnosisandWeight-RelatedCounseling,”PatientEducationandCounseling82,no.1(2011):123-29,

/10.1016/j.pec.2010.02.018

.

ObesityandGLP-1Drugs3

behavioralhealthservices,butin2024,only12.4percentofpatientsdid,arelativedecreaseof

73.7percent.

Background

ObesityisacommonandseriousdiseasethataffectsmorethantwoinfiveAmericanadults.

2

Itisdefinedinadultsashavingabodymassindex(BMI)of30orhigher,whereasoverweightisdefinedashavingaBMIof25orhigherbutlessthan30.

3

HavingaBMIof40orhigherisconsideredsevereormorbid

obesity.

4

Obesityincreasestheriskofsuchhealthconditionsastype2diabetes,cardiovasculardisease,musculoskeletaldisorders(e.g.,osteoarthritis)andcertaincancers.

5

Inrecentyears,anewclassofmedicationsforobesityhasbecomeavailable:glucagon-likepeptide-1

(GLP-1)receptoragonists.

6

TheseGLP-1drugsareanalogsofanaturallyoccurringhormonethat

stimulatessecretionofinsulin(ahormonethatdecreasesbloodsugarlevels),inhibitssecretionof

glucagon(ahormonethatincreasesbloodsugarlevels)andinhibitsappetiteandfoodintake.

7

,

8

GLP-1isbrokendownquicklyinhumans,butGLP-1drugsarelongerlasting.

9

TheFoodandDrugAdministration(FDA)approvedthefirstGLP-1drug,Byetta(exenatide),forthe

treatmentoftype2diabetesin2005.

10

Sincethen,otherGLP-1drugshavebeenintroduced,including

threeapprovedforweightmanagementinpatientswhoareobeseorwhoareoverweightwithatleastoneweight-relatedcomorbidcondition:Saxenda(liraglutide;approved2014),Wegovy(semaglutide;approved2021)andadualglucose-dependentinsulinotropicpolypeptide(GIP)receptorandGLP-1drug,

Zepbound(tirzepatide;approved2023).

11

,

12

,

13

,

14

GLP-1drugsareincreasinglyprescribed.From2020to2022,thevolumeofGLP-1prescriptionsgrew300percent.

15

Justoverhalf(53.8percent)ofpatientstakingaGLP-1drugin2022hadahistoryoftype

2“AdultObesityFacts,”CentersforDiseaseControlandPrevention(CDC),May14,2024,

/obesity/adult-obesity-facts/index.html

.

3“Data,Trends,andMapsDefinitionsandSources:ObesityandWeightStatus,”CDC,October21,2024,

/dnpao-data-trends-maps/database/definitions.html

.

4“AdultBMICategories,”CDC,March19,2024,

/bmi/adult-calculator/bmi-categories.html

.

5“Obesity:HealthConsequencesofBeingOverweight,”WorldHealthOrganization,March1,2024,

/news-room/questions-and-answers/item/obesity-health-consequences-of-being-overweight

.

6“GLP-1Agonists,”ClevelandClinic,lastreviewedJuly3,2023,

/health/treatments/13901-glp-1-agonists

.

7JensJuulHolst,“FromtheIncretinConceptandtheDiscoveryofGLP-1toToday’sDiabetesTherapy,”FrontiersinEndocrinology10(2019):260,

/10.3389/fendo.2019.00260

.

8“Glucagon,”ClevelandClinic,lastreviewedJanuary21,2025,

/health/articles/22283-

glucagon

.

9Holst,“FromtheIncretinConceptandtheDiscoveryofGLP-1toToday’sDiabetesTherapy.”

10“GLP-1Agonists,”ClevelandClinic.

11“UpdateonFDA’sOngoingEvaluationofReportsofSuicidalThoughtsorActionsinPatientsTakingaCertainTypeofMedicinesApprovedforType2DiabetesandObesity,”USFoodandDrugAdministration,January11,2024,

/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-

actions-patients-taking-certain-type

.

12“Saxenda(liraglutide)injection3mg[prescribinginformation],”NovoNordisk,revisedNovember2024,

/saxenda.pdf

.

13“Wegovy(semaglutide)injection2.4mg[prescribinginformation],”NovoNordiskA/S,revisedNovember2024,

/wegovy.pdf

.

14“Zepbound—tirzepatideinjection,solution[prescribinginformation],”EliLillyandCompany,revisedDecember2024,

/zepbound/zepbound.html#pi

.

15SanjulaJain,KatiePatton,AustinMilleretal.,2023TrendsShapingtheHealthEconomy:ValueforMoney,TrilliantHealth,2023,

/hubfs/2024%20Website%20Redesign/Reports/2023%20Annual%20Report%20FINAL.

pdf

.

ObesityandGLP-1Drugs4

2diabetes,suggestingthattheremainderofpatientstakingthedrugdidsoforotherindications,includingobesity.

16

Apollin2024foundthat12percentofadultshadtakenaGLP-1drug,and6percentwere

currentlytakingone.

17

ThemostcommonsideeffectsofGLP-1drugsaregastrointestinalsymptoms,principallynauseabutalsovomiting,diarrheaandconstipation.

18

,

19

Lesscommonbutmoreserioussideeffectsincludepancreatitis,gastroparesis,bowelobstruction,gallstoneattacksandbileductblockage.

20

WeightlostduetoGLP-1

drugsmayberegainedifthedrugsarestopped.

21

,

22

GLP-1drugshavebeenassociatedwithcardiovascularbenefit.

23

Onesuchdrug,Wegovy,isindicatedforreducingtheriskofmajoradversecardiovasculareventsinadultswithcardiovasculardiseaseandeitherobesityoroverweight.

24

GLP-1drugsalsoareunderstudyforpotentialbenefitsrelatedtodepressionandanxiety,

25

Alzheimer’sdisease,Parkinson’sdisease,osteoarthritis,substanceusedisordersand

nonalcoholicfattyliverdisease.

26

Thereisevidencethatbariatricsurgery,atypeofoperationtomodifythestomachandintestinestotreatobesity,

27

isbeingperformedlessasGLP-1drugsbecomemorecommonlyused.Across-sectionalstudyofprivatelyinsuredpatientsfoundarelative105.6percentincreaseinpatientsprescribedGLP-1drugsasanti-obesitymedicationsfrom2022to2023,witharelative8.7percentdecreaseinpatientsreceivingbariatricsurgeryduringthesameperiod.

28

TheUSPreventiveServicesTaskForce(USPSTF)recommendsintensive,multicomponentbehavioralinterventionsforadultswithobesity.

29

Manyoftheeffectivebehavioralweightlossinterventions

16Jainetal.,2023TrendsShapingtheHealthEconomy.

17AlexMontero,GraceSparks,MarleyPresiadoandLizHamel,“KFFHealthTrackingPollMay2024:ThePublic’s

UseandViewsofGLP-1Drugs,”KFF,May10,2024,

/health-costs/poll-finding/kff-health-tracking-

poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/?source=email

.

18TheodosiosD.Filippatos,ThaliaV.PanagiotopoulouandMosesS.Elisaf,“AdverseEffectsofGLP-1ReceptorAgonists,”ReviewofDiabeticStudies11,no.3-4(2014):202-30,

/26177483/

.

19LisaCatanese,“GLP-1DiabetesandWeight-LossDrugSideEffects:‘OzempicFace’andMore,”HarvardHealth

Publishing,February5,2024,

/staying-healthy/glp-1-diabetes-and-weight-loss-drug-

side-effects-ozempic-face-and-more

.

20Catanese,“GLP-1DiabetesandWeight-LossDrugSideEffects.”

21SadiyaS.Khan,ChiadiE.NdumeleandDhruvS.Kazi,“DiscontinuationofGlucagon-LikePeptide-1ReceptorAgonists,”JAMA333,no.2(2025):113-14,

/10.1001/jama.2024.22284

.

22KerstenBartelt,ChrisMast,JoeDeckert,MatthewGracianetteandBrendanJoyce,“ManyPatientsMaintainWeightLossaYearAfterStoppingSemaglutideandLiraglutide,”EpicResearch,January23,2024,

/articles/many-patients-maintain-weight-loss-a-year-after-stopping-semaglutide-and-

liraglutide

.

23LamijaFerhatbegović,DenisMršićandAmraMacić-Džanković,“TheBenefitsofGLP1ReceptorsinCardiovascularDiseases,”FrontiersinClinicalDiabetesandHealthcare4(2023):1293926,

/10.3389/fcdhc.2023.1293926

.

24“Wegovy(semaglutide)injection2.4mg[prescribinginformation],”NovoNordiskA/S.

25AnnaMiller,BrendanJoyce,KerstenBarteltandJoeDeckert,“MostGLP-1MedicationsCorrelatedwithaLowerLikelihoodofAnxietyandDepressionDiagnoses,”EpicResearch,February6,2024,

/articles/most-glp-1-medications-correlated-with-a-lower-likelihood-of-anxiety-and-

depression-diagnoses

.

26KristinAllen,PaulLovoyandMarilynN.Bulloch,“FiveUnexpectedNewUsesforGLP-1ReceptorAgonists,”PharmacyTimes—PharmacyPracticeinFocus:HealthSystems13,no.3(May2024),

/view/five-unexpected-new-uses-for-glp-1-receptor-agonists

.

27“BariatricSurgeryProcedures,”AmericanSocietyforMetabolicandBariatricSurgery,accessedApril3,2025,

/patients/bariatric-surgery-procedures/

.

28KevinLin,AteevMehrotraandThomasC.Tsai,“MetabolicBariatricSurgeryintheEraofGLP-1ReceptorAgonistsforObesityManagement,”JAMANetworkOpen7,no.10(2024):e2441380,

/10.1001/jamanetworkopen.2024.41380

.

29USPreventiveServicesTaskForce(USPSTF),WeightLosstoPreventObesity-RelatedMorbidityandMortalityinAdults:BehavioralInterventions,finalrecommendationstatement,September18,2018,

/uspstf/recommendation/obesity-in-adults-interventions

.

ObesityandGLP-1Drugs5

consideredbytheUSPSTFinvolvedacombinationofdietarychangesandincreasedphysicalactivity.

30

BehavioralhealthservicesalsoarerelevanttopatientsusingGLP-1drugstotreatobesitybecauseofevidencethatpatientsonsuchdrugshaveanelevatedriskofpsychiatricdisorders,includingmajor

depression,anxietyandsuicidalbehavior.

31

Inthisreport,FAIRHealthdelvesintoitsrepositoryofover51billioncommercialhealthcareclaim

records,thenation’slargestsuchdatabase,toexaminetrendsinobesityandGLP-1drugprescriptionsamongadultpatientsduringtheperiod2019-2024.Thisstudyfocusesontrendsindiagnosisof

overweight,obesityandtype2diabetes,aswellasGLP-1drugsandotherobesitytreatmentoptions(includingbariatricsurgeryandbehavioralhealthservices).

Methodology

Overweightorobesityandtype2diabetesdiagnoseswereidentifiedinacohortofpatientsinFAIR

HealthlongitudinalclaimsdatafromJanuary1,2019,toDecember31,2024,usingICD-10diagnosis

codesthatappearedinthefirstthroughsixthdiagnosiscodepositionsontheclaims.Onlyclaimswith

codesbeginningwithE66weretaggedashavingapositivediagnosisforoverweightorobesity;themerepresenceofaZdiagnosiscodestatingaBMIthatqualifiedforthatdiagnosiswasnotsufficient.Patientswereincludedwithadiagnosisofoverweightorobesityonlyintheyearswhenthatdiagnosisappearedinconnectionwithanymedicalservicetheyreceived.Morbid,orsevere,obesitywasdefinedbythecode

E66.01.CodesbeginningwithE11wereincludedfortype2diabetes.Claimsfromworkers’compensationwereexcluded.Claimsfromcontributorswhodidnotgivedatafortheentiretyofagivenyearwere

excludedfromthatyear.Patientswhowereenrolledonlyforamonthwerestillcountedinthedenominatorfortheyear.

GLP-1prescriptionswereidentifiedfromasubsetofdatacontributorswhogavelinkablemedicalandprescriptionclaimsdatafromJanuary1,2019,toDecember31,2024,usingNationalDrugCode(NDC)codesidentifyingthesedrugs.

BariatricsurgerieswereidentifiedusingacombinationofICD-10procedurecodesandCPT®

32

codes

relatedtobariatricsurgerythatwereaccompaniedbyspecificICD-10diagnosiscodesrelatedtoobesityappearinginthefirstthroughfourthpositionsontheclaim.

BehavioralhealthserviceswereidentifiedusingCPTandHCPCScodesfortheseservices—including

psychotherapy,nutritiontherapyandotherinterventions—onclaimlineswhereoverweightorobesitywaslistedasadiagnosisinthefirstthroughsixthpositionsontheclaim.Tobeincluded,theservicemusthavebeenbilledwithanobesity-specificdiagnosiscode.

Forpurposesofthisstudy,geographywasbasedonimputedhomestateofthepatient.Thisvalueis

uniqueonanannualbasisandimputedbasedonthepatient’sclaimsdata.Ageandgenderwerealso

imputedbasedonthemostcommonlyoccurringageineachpatient’sclaimsforeachcalendaryearandthemostcommonlyoccurringgenderineachpatient’sclaimsforthestudyperiod.Allresultswerelimitedtoadultpatients,i.e.,thoseaged18andolder.

30USPSTF,WeightLosstoPreventObesity-RelatedMorbidityandMortalityinAdults.

31EdyKornelius,Jing-YangHuang,Shih-ChangLo,Chien-NingHuangandYi-SunYang,“TheRiskofDepression,Anxiety,andSuicidalBehaviorinPatientswithObesityonGlucagonLikePeptide-1ReceptorAgonistTherapy,”

ScientificReports14(October18,2024):24433,

/10.1038/s41598-024-75965-2

.

32CPT©2024AmericanMedicalAssociation(AMA).Allrightsreserved.

ObesityandGLP-1Drugs6

Tocapturepotentialsideeffects,professionalandfacilityclaimswerepulledforpatientsfromtheindexdateofGLP-1prescription(thefirstdateitappearedinthedata)to364daysbeforetoidentifythetimeperiodbefore,and365daysforwardtoidentifythetimeperiodafter.

Limitations

Thedatausedinthisreportcompriseclaimsdataforcommerciallyinsuredpatientswhoarecoveredbyinsurersandthird-partyadministratorswhovoluntarilyparticipateinFAIRHealth’sdatacontribution

program.MedicareAdvantage(MedicarePartC)enrolleesfromcontributinginsurersareincluded,but

notparticipantsinMedicarePartsA,BandD.

33

Inaddition,datafromMedicaid,CHIPandotherstateandlocalgovernmentinsuranceprogramsarenotincluded,noraredatacollectedregardinguninsured

patients.

ThisisanobservationalreportbasedonthedataFAIRHealthreceivesfromprivatepayorsregardingcarerenderedtocoveredpatients.Homestateofpatientsisimputedbasedonthepatient’sclaimsdataeachyear.Prescriptiondataarelimitedtoasubsetofdatacontributorswhogavelinkablemedicalandprescriptionclaimsdata.

Thereportwasnotsubjecttopeerreview.

33FAIRHealthalsoreceivestheentirecollectionofclaimsfortraditionalMedicarePartsA,BandDunderthe

CentersforMedicare&MedicaidServicesQualifiedEntityProgram,butthosedataarenotasourceforthisreport.

ObesityandGLP-1Drugs7

Results

OverweightandObesityTrends

From2019to2024,thepercentageofadultpatientswithadiagnosisofoverweightorobesityincreased50.7percent,from10.4percentin2019to15.7percentin2024(figure1).Figure1alsoshowsasubsetofthesepatientswhowerediagnosedwithmorbidobesity.Thepercentageofadultpatientswithmorbidobesityclimbedfrom3.1percentin2019to5.2percentin2024,arelativeincreaseof70.9percent.

Thesepercentagesdifferfromwhathasbeenreportedinotherdata.Forexample,theCentersfor

DiseaseControlandPrevention(CDC)foundthat40.3percentofadultsover20wereobesewhile9.4

percentwereseverely(morbidly)obeseduringtheperiod2021-2023.

34

Notably,theCDCuseddatafromsurveysofthegeneralpopulation,whileFAIRHealthdataincludeonlycommerciallyinsuredpatients.Inaddition,manyadultpatientswhoareoverweightorobesemaynotobtainanycareintheyearand/or

receiveamedicaldiagnosisofoverweightorobesity;

35

thus,theyareunderrepresentedinmedicalclaims-baseddata.

Percentofadultpatients

18%

16%

14%

12%

10%

8%

6%

4%

2%

0%

201920202021202220232024

Year

PercentofAdultPatientswithaDiagnosisofOverweightorObesity

PercentofAdultPatientswithaDiagnosisofMorbidObesity

Figure1.Percentofadultpatientsbydiagnosisandyear,2019-2024

34SamuelD.Emmerich,CherylD.Fryar,BryanStiermanandCynthiaL.Ogden,ObesityandSevereObesity

PrevalenceinAdults:UnitedStates,August2021–August2023,NationalCenterforHealthStatistics(NCHS)DataBrief,no508(2024),

/nchs/products/databriefs/db508.htm

.

35SaraN.Bleich,OctaviaPicket-BlakelyandLisaA.Cooper,“PhysicianPracticePatternsofObesityDiagnosisandWeight-RelatedCounseling,”PatientEducationandCounseling82,no.1(2011):123-29,

/10.1016/j.pec.2010.02.018

.

ObesityandGLP-1Drugs8

Thepercentageofadultpatientswithanoverweightorobesitydiagnosisvariedbyageandoverthe

studyperiod(figure2).In2019,theagegroup50-64hadthehighestpercentageofpatientswith

overweightorobesitydiagnoses(13.0percent).Thesameagegrouphadthehighestpercentagein2023and2024,andthepercentageincreasedeachyear(18.1percentin2023and19.3percentin2024).

However,in2020,2021and2022,theagegroup65-74hadthehighestpercentageofpatientsamongthosewithanoverweightorobesitydiagnosis.Intheagegroups50andover,therewasaconsistentupwardtrendineveryyearfrom2019to2024.Ineveryagegroup,therewasapercentincreasefrom2019to2024(table1).

Percentofpatientswithanoverweightorobesitydiagnosis

20%

18%

16%

14%

12%

10%

8%

6%

4%

2%

0%18to2930to3940to4950to6465to7475andupAgegroup

201920202021202220232024

Figure2.Percentofpatientswithanoverweightorobesitydiagnosisbyagegroupandyear,2019-2024

ObesityandGLP-1Drugs9

Table1.Percentofpatientswithanoverweightorobesitydiagnosisbyagegroupandyearwithpercentchange,2019-2024

AgeGroup

2019

2024

PercentChange

18to29

5.4%

8.2%

52.2%

30to39

9.1%

14.1%

55.6%

40to49

12.1%

18.0%

49.3%

50to64

13.0%

19.3%

48.5%

65to74

12.5%

18.8%

50.9%

75andup

9.3%

14.2%

53.5%

Figure3showsthepercentageofmedicalclaimlinesforprofessionalservicesrenderedviatelehealthineachyearfrom2019to2024.Thepercentageofmedicalclaimlinesfortelehealthserviceswithaprimarydiagnosisofoverweightorobesityexceededthoseforprimarydiagnosesotherthanoverweightor

obesitythroughoutthestudyperiod.Bothrosesharplyin2020astelehealthbecameapopularvenueofcareduringtheCOVID-19pandemic,thenbothfellin2021,thoughnottopre-pandemiclevels.Overthestudyperiod,claimlinesfortelehealthservicesassociatedwithaprimarydiagnosisofoverweightor

obesityclimbedfrom0.3percentofallmedicalclaimlinesin2019to10.3percentin2024,arelative

increaseof3,483.3percent.Bycomparison,telehealthservicesforprimarydiagnosesotherthan

overweightorobesityincreasedfrom0.1percentin2019to4.4percentin2024,a3,235.7percentrise.

Percentofprofessionalclaimlines

14%

renderedviatelehealth

12%

10%

8%

6%

4%

2%

0%

2020

2021

2022

2023

2024

2019

Year

PrimaryDiagnosisofOverweightorObesity

PrimaryDiagnosisOtherThanOverweightorObesity

Figure3.Percentofprofessionalclaimlinesrenderedviatelehealthbydiagnosisandyear,2019-2024

ObesityandGLP-1Drugs10

Outofalltelehealthclaimlines,thepercentageofclaimlinesassociatedwithanoverweightorobesitydiagnosisclimbedfrom2019to2024(figure4).In2019,thepercentageoftelehealthclaimlinesforoverweightorobesitywas1.5percent,butin2024,itwas3.5percent,arelativeincreaseof126.9

percent.

Percentofteleheaalthclaimlines

4.0%

3.5%

3.0%

2.5%

2.0%

1.5%

1.0%

0.5%

0.0%

201920202021202220232024

Year

DiagnosisofOverweightorObesity

Figure4.Overweightorobesityclaimlinesfortelehealthservicesasapercentageofalltelehealthclaimlines

ObesityandGLP-1Drugs11

Type2DiabetesTrends

Thepercentageofadultpatientswhohadadiagnosisoftype2diabeteswasrelativelystablefrom2019to2021andthenrosesteadilyfrom2022to2024(figure5).In2019,thepercentageofsuchpatientswas9.7percent;itdroppedto9.5percentin2021,thenroseto11.7percentin2024,anoverallrelative

increaseof21.2percent(2019-2024).In2023,10.9percentofadultpatientshadatype2diabetes

diagnosis.ThisalignscloselywiththeCDC’sfindingof11.3percentprevalenceofdiagnoseddiabetesinadultsaged20andolderfrom2021to2023.

36

Percentofadultpatients

14%

12%

10%

8%

6%

4%

2%

0%

201920202021202220232024

Year

PercentofAdultPatientswithaDiagnosisofType2Diabetes

Figure5.Adultpatientswithatype2diabetesdiagnosisasapercentageofalladultpatientsbyyear,2019-2024

36JaneA.Gwira,CherylD.FryarandQiupingGu,PrevalenceofTotal,DiagnosedandUndiagnosedDiabetesinAdults:UnitedStates,August2021–August2023,NCHSDataBrief,no.516(2024),

/nchs/products/databriefs/db516.htm

.

ObesityandGLP-1Drugs12

Thepercentageofadultpatientswithatype2diab